U.S. markets close in 2 hours 11 minutes
  • S&P 500

    3,781.77
    -13.77 (-0.36%)
     
  • Dow 30

    30,912.57
    -78.95 (-0.25%)
     
  • Nasdaq

    13,078.80
    -33.83 (-0.26%)
     
  • Russell 2000

    2,133.86
    -21.49 (-1.00%)
     
  • Crude Oil

    52.30
    -1.27 (-2.37%)
     
  • Gold

    1,828.10
    -23.30 (-1.26%)
     
  • Silver

    24.83
    -0.97 (-3.77%)
     
  • EUR/USD

    1.2085
    -0.0071 (-0.58%)
     
  • 10-Yr Bond

    1.0920
    -0.0370 (-3.28%)
     
  • GBP/USD

    1.3583
    -0.0109 (-0.79%)
     
  • USD/JPY

    103.8600
    +0.0440 (+0.04%)
     
  • BTC-USD

    35,218.58
    -2,620.06 (-6.92%)
     
  • CMC Crypto 200

    675.35
    -59.79 (-8.13%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.08 (-0.62%)
     

CytRx receives FDA approval to continue aldoxorubicin clinical trial

CytRx announced it has received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas. The clinical trial is scheduled to begin this quarter. For purposes of the clinical trial, disease progression is defined as an increase in the size of measurable tumors by 20% or the development of a new tumor lesion.